Trial Profile
Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs PCAR 019 (Primary)
- Indications B-cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors PersonGen Biomedicine
- 03 Aug 2016 New trial record